← Back to screener

LIGAND PHARMACEUTICALS INC LGND

Rank #1848 · Nasdaq · $6.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
40.7
P/E
124.0
P/B
10.83
ROE
8.7%
Op. Margin
9.1%
Debt Ratio
19%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E 124.0x, P/B 10.83x. Ranks in the top 71% of the universe.

Profitability ★★★☆☆
Average

ROE 8.7%. Ranks in the top 47% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 19%. Ranks in the top 13% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 33.1% year over year. Ranks in the top 95% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$-0.0B-25.6-695
2012$0.0B$-0.0B$-0.0B$0.0B-124.51271
2013$0.0B$-0.0B$0.0B$0.0B-2.9294
2014$0.0B$0.0B$-0.0B$0.0B0.6111
2015$0.0B$0.0B$0.0B$0.0B30.5888
2016$0.1B$0.0B$0.0B$0.2B30.495
2017$0.1B$0.0B$0.2B$0.3B38.068
2018$0.1B$0.0B$-0.0B$0.4B40.363
2019$0.1B$0.1B$0.0B$0.6B48.2125
2020$0.3B$0.2B$0.1B$0.8B65.195
2021$0.1B$0.8B$0.6B$0.6B671.0116
2022$0.2B$0.0B$-0.0B$0.8B22.962
2023$0.2B$0.1B$0.1B$0.7B43.023
2024$0.2B$0.0B$-0.0B$0.8B1.511
2025$0.1B$0.0B$0.1B$0.6B9.119

← See the full screener